WAYNE, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (TFX) (NYSE:TFX), a leading global provider of medical technologies, announced today that a new peer-reviewed study in the Nature ...

Teleflex TFX recently announced the upcoming full market release of the Advanced Tissue Control (“ATC”) feature on its unified UroLift 2 System — a platformdesigned for the treatment of benign ...

WAYNE, Pa.--(BUSINESS WIRE)--NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE: TFX) focused on addressing unmet needs in the field of urology, today announced that the U.S. Food and ...

WAYNE, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced that 200,000 patients have been treated with the minimally invasive UroLift ® System for benign ...

NeoTract, Inc., today announced that the Centers for Medicare and Medicaid Services (CMS) have issued two new codes that describe the UroLift® implant procedure for the treatment of enlarged prostate ...

Presentations at the 37th Annual European Association of Urology Congress to Demonstrate Measurable and Sustained Improvement of BPH Symptoms and IPSS Scores WAYNE, Pa., July 01, 2022 (GLOBE NEWSWIRE) ...

The committee concluded that UroLift is clinically effective, with sustained relief of lower urinary tract symptoms up to 5 years after treatment. It is implanted using a minimally invasive procedure.

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX) today announced that 100,000 patients have been treated globally with its minimally invasive UroLift ® System, a safe and effective ...